Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and...

Full description

Bibliographic Details
Main Authors: Yuxin Ma, Xinhong Shi, Kun Zhao, Shuyi Hu, Yue Shi, Yingying Jiang, Yiling Liu, Lin Lu, Yuting Chang, Fei Zhou, Yingying Dai, Zipeng Wu, Shiyi Li, Zhiying Qian, Xia Xu, Chenchen Li, Bo Shen, Guoren Zhou, Cheng Chen, Xiaohua Wang, Jifeng Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
metastatic triple negative breast cancer (mTNBC)
immune checkpoint inhibitors (ICIS)
tislelizumab
eribulin mesylate
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1328844/full

Similar Items